Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech).
作者信息
Hamada Yohhei
机构信息
Institute for Global Health, University College London, 3rd floor, Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.
出版信息
J Pharm Policy Pract. 2021 Aug 4;14(1):65. doi: 10.1186/s40545-021-00354-3.
Abstract
摘要
相似文献
1
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech).托珠单抗（BNT162b2，辉瑞-生物科技公司）接种后颅内出血分析。
J Pharm Policy Pract. 2021 Aug 4;14(1):65. doi: 10.1186/s40545-021-00354-3.
2
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech).在接受托珠单抗（BNT162b2，辉瑞-生物科技公司）的日本女性中可能出现的不良事件。
J Pharm Policy Pract. 2021 May 31;14(1):46. doi: 10.1186/s40545-021-00326-7.
3
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.免疫实践咨询委员会关于辉瑞-BioNTech COVID-19 疫苗在 12-15 岁青少年中使用的临时建议-美国，2021 年 5 月。
MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):749-752. doi: 10.15585/mmwr.mm7020e1.
4
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.慢性透析患者 COVID-19 疫苗接种的免疫原性。
Front Immunol. 2021 Jun 30;12:690698. doi: 10.3389/fimmu.2021.690698. eCollection 2021.
5
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.免疫实践咨询委员会关于使用辉瑞-BioNTech COVID-19 疫苗的临时建议-美国，2020 年 12 月。
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. doi: 10.15585/mmwr.mm6950e2.
6
A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.一位 59 岁女性，在接种第一剂辉瑞-生物科技 BNT162b2 mRNA COVID-19 疫苗后 7 天出现广泛的深静脉血栓形成和肺血栓栓塞症。
Am J Case Rep. 2021 Jun 12;22:e932946. doi: 10.12659/AJCR.932946.
7
Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19.接种 COVID-19 疫苗（tozinameran）后出现三叉神经和颈神经根炎。
BMJ Case Rep. 2021 Jun 21;14(6):e242344. doi: 10.1136/bcr-2021-242344.
8
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
9
Acute myocarditis following administration of BNT162b2 vaccine.接种BNT162b2疫苗后发生的急性心肌炎。
IDCases. 2021 Jun 16;25:e01197. doi: 10.1016/j.idcr.2021.e01197. eCollection 2021.
10
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.BNT162b2（辉瑞/生物科技）疫苗在第 2 剂接种后 ≥7 天对 COVID-19 的有效率为 95%。
Ann Intern Med. 2021 Feb;174(2):JC15. doi: 10.7326/ACPJ202102160-015. Epub 2021 Feb 2.
本文引用的文献
1
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech).在接受托珠单抗（BNT162b2，辉瑞-生物科技公司）的日本女性中可能出现的不良事件。
J Pharm Policy Pract. 2021 May 31;14(1):46. doi: 10.1186/s40545-021-00326-7.
Zotero 插件